• Navigating Regulatory Challenges and Ensuring Safety in the Psychedelics Industry
    Aug 26 2023

    "Balancing Medical Promise and Regulatory Complexity in the Psychedelics Landscape"

    The "Psychedelics Capital Podcast" host Ross O'Brien  from Bonaventure Equity interviews Michael Werner from Holland & Knight, discussing the regulatory landscape for psychedelics. Michael, a partner at the law firm, explains that while the FDA sees itself as a public health agency focused on ensuring safe and effective products, the DEA approaches controlled substances like psychedelics from a law enforcement perspective due to their potential dangers. He highlights that while many drugs, including psychedelics, have potential benefits, the FDA emphasizes the importance of rigorous clinical trials to establish their safety and efficacy, particularly in a landscape where recreational and unregulated use is also prevalent.

     

    Produced by PodConx

    Ross O'Brien -  https://www.linkedin.com/in/rossobrien/

    Bonaventure Equity - https://link.bve.vc/Visit-Us

    Michael Warner - https://www.linkedin.com/in/michael-werner-a402189/

    Holland & Knight - https://www.hklaw.com/

    Show More Show Less
    55 mins
  • Unleashing the Power of Psychedelics and AI: Revolutionizing Mental Health with Sensorium Therapeutics
    Jul 6 2023

    Exploring the Potential of Psychedelics and Natural Compounds

    Dick Simon, the founder of Sensorium Therapeutics, discusses his journey and motivation in the field of psychedelics. Inspired by a friend's success with psychedelics in treating mental health issues, Dick embarked on a mission to advance research and de-stigmatization. He he joins Ross O'Brien  from Bonaventure Equity to talk about  co-founding Sensorium to create novel pharmaceuticals using a comprehensive database of psychoactive plants and fungi, leveraging artificial intelligence and machine learning for drug discovery. The company aims to have a significant impact in mental health and provide alternative treatment options for those who may not benefit from traditional psychedelics therapies.

    Produced by PodConx

    Ross O'Brien -  https://www.linkedin.com/in/rossobrien/

    Bonaventure Equity - https://link.bve.vc/Visit-Us

    Dick Simons - https://www.linkedin.com/in/dick-simon-6050ba5/

    Sensorium Therapeutics - https://www.sensorium.bio/

     

    Show More Show Less
    25 mins
  • Cliché Busting: Navigating the Legal Challenges of the Cannabis and Psychedelic Industries
    Mar 30 2023

    Jennifer Fisher and Bill Growney, two partners at Goodwin Proctor, a law firm specializing in the cannabis industry join Ross O'Brien  from Bonaventure Equity to talk about their practice and their work advising companies in the cannabis and psychedelic spaces. The conversation covers topics such as regulatory compliance, legal challenges, and unique challenges faced by emerging companies in these industries.

     

    Produced by PodConX

    Ross O'Brien -  https://www.linkedin.com/in/rossobrien/

    Bonaventure Equity - https://link.bve.vc/Visit-Us

    Jennifer Fisher - https://www.linkedin.com/in/jennifer-briggs-fisher-14843a/

    Bill Growney - https://www.linkedin.com/in/billgrowney/

    Goodwin Proctor - https://www.goodwinlaw.com/en

    Show More Show Less
    43 mins
  • Exploring the Future of Psychedelic Medicine: An Entrepreneur's Journey with Greg McKee
    Mar 23 2023

    In this episode host Ross O'Brien  from Bonaventure Equity interviews Greg McKee, the founder and CEO of Journey Life Sciences and a managing partner at Bonaventure Equity. O'Brien and McKee discuss the emerging world of psychedelics and venture capital, and the need for new paradigms of medicine to address the mental health, addiction, and pain epidemics. They talk about entrepreneurship and the importance of testing the market demand for new ideas, especially in the context of psychedelics as potential therapeutics. McKee shares his background in finance and drug development, and how he came to be interested in psychedelics. The episode concludes with a discussion of Journey's mission and how the company is working to bring psychedelic therapies to market.

    Produced by PodConX

    Ross O'Brien -  https://www.linkedin.com/in/rossobrien/

    Bonaventure Equity - https://link.bve.vc/Visit-Us

    Greg McKee - https://www.linkedin.com/in/gregorymmckee/

     

    Show More Show Less
    44 mins
  • Nick Norris
    Mar 9 2023

    Deep preparation, with a focus on integration and continued therapy

    U.S. Navy SEAL veteran, entrepreneur, and founder of Protekt Products Nick Norris joins Ross O'Brien  from Bonaventure Equity to explain how psychedelic therapy helped him reignite his passions, restore his connection with his family, and give him a second chance at appreciating life.  He explains how Veterans Exploring Treatment Solutions (VETS) helps U.S. military veterans seeking psychedelic-assisted therapies for traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), addiction, and other health conditions.

    Produced by PodConX

     

    Ross O'Brien -  https://www.linkedin.com/in/rossobrien/

    Bonaventure Equity - https://link.bve.vc/Visit-Us

    Veterans Exploring Treatment Solutions (VETS) - https://vetsolutions.org/

    Protekt - https://protekt.com/

     

     

    Show More Show Less
    53 mins
  • Trailer
    Feb 5 2023

    Welcome to Psychedelic Capital a show about investing in the new frontier of life sciences.  Premiering March 9th, join Bonaventure Capital's CEO Ross O'Brien as he tackles some of health cares biggest challenges with key thought-leaders, investors and entrepreneurs.  

    Produced by PodConx

    Ross O'Brien - https://www.linkedin.com/in/rossobrien/

    Bonaventure Equity: Life Sciences Venture Capital - https://www.bve.vc/

    Recorded on Squadcast

    Show More Show Less
    1 min